{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:47:23Z","timestamp":1787496443202,"version":"build-2736575974"},"reference-count":27,"publisher":"The Journal of Rheumatology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2013,5]]},"abstract":"\n Objective.<\/jats:title>\n \n This posthoc analysis evaluated the percentage of patients with psoriatic arthritis (PsA) who achieved minimal disease activity (MDA) and compared the results with a modified MDA substituting the physician global assessment (PGA) for the Psoriasis Activity and Severity Index (PASI) using data from the ADalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT;\n NCT00646386<\/jats:ext-link>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Methods.<\/jats:title>\n \n Patients with active PsA were randomized to receive adalimumab 40 mg or placebo every other week for 24 weeks. MDA was defined as achieving \u2265 5 of the following criteria: tender joint count \u2264 1; swollen joint count \u2264 1; PASI \u2264 1 or body surface area \u2264 3%; patient pain score \u2264 15 [1\u2013100 mm visual analog scale (VAS)]; patient global assessment (PGA) of disease activity \u2264 20 (1\u2013100 mm VAS); Health Assessment Questionnaire \u2264 0.5; and tender entheseal points \u2264 1 (only heels assessed). For modification of the MDA, PASI \u2264 1 was substituted with PGA \u201cClear\u201d as MDA\n PGA1<\/jats:sub>\n and PGA \u201cClear\u201d or \u201cAlmost clear\u201d as MDA\n PGA2<\/jats:sub>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Results.<\/jats:title>\n \n Sixty-seven patients were treated with adalimumab and 69 with placebo. At Week 24, MDA, MDA\n PGA1<\/jats:sub>\n , and MDA\n PGA2<\/jats:sub>\n were achieved by 39%, 37%, and 39%, respectively, of patients treated with adalimumab versus 7%, 5%, and 8% of patients on placebo (p < 0.001). Kappa coefficients indicated good agreement between PASI and PGA at Week 24.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion.<\/jats:title>\n ADEPT results indicated that significantly more patients treated with adalimumab achieved MDA by Week 24 compared with placebo. Modification of the MDA by replacing PASI \u2264 1 with PGA assessments did not alter the results, which may improve feasibility of practical use of the index.<\/jats:p>\n <\/jats:sec>","DOI":"10.3899\/jrheum.120970","type":"journal-article","created":{"date-parts":[[2013,3,16]],"date-time":"2013-03-16T03:42:35Z","timestamp":1363405355000},"page":"647-652","source":"Crossref","is-referenced-by-count":40,"title":["Application and Modifications of Minimal Disease Activity Measures for Patients with Psoriatic Arthritis Treated with Adalimumab: Subanalyses of ADEPT"],"prefix":"10.3899","volume":"40","author":[{"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Heckaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Kary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Kupper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2013,3,15]]},"reference":[{"key":"2018112909313190000_40.5.647.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.140582"},{"key":"2018112909313190000_40.5.647.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.040"},{"key":"2018112909313190000_40.5.647.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094946"},{"key":"2018112909313190000_40.5.647.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"2018112909313190000_40.5.647.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"2018112909313190000_40.5.647.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"2018112909313190000_40.5.647.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"2018112909313190000_40.5.647.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150995"},{"key":"2018112909313190000_40.5.647.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092767"},{"key":"2018112909313190000_40.5.647.10","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20577"},{"key":"2018112909313190000_40.5.647.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.123919"},{"key":"2018112909313190000_40.5.647.12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101116"},{"key":"2018112909313190000_40.5.647.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2018112909313190000_40.5.647.14","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-38"},{"key":"2018112909313190000_40.5.647.15","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20162"},{"key":"2018112909313190000_40.5.647.16","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20155"},{"key":"2018112909313190000_40.5.647.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.031237"},{"key":"2018112909313190000_40.5.647.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.01.022"},{"key":"2018112909313190000_40.5.647.19","first-page":"260","article-title":"The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area and Severity Index (PASI) and physician\u2019s global assessment (PGA): A comparison","volume":"2","author":"Gottlieb","year":"2003","journal-title":"J Drugs Dermatol"},{"key":"2018112909313190000_40.5.647.20","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"2018112909313190000_40.5.647.21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1590\/S0365-05962010000500005","article-title":"Inter-rater concordance study of the PASI (Psoriasis Area and Severity Index)","volume":"85","author":"Faria","year":"2010","journal-title":"An Bras Dermatol"},{"key":"2018112909313190000_40.5.647.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06035.x"},{"key":"2018112909313190000_40.5.647.23","first-page":"2262","article-title":"Outcome measures in psoriatic arthritis","volume":"32","author":"Gladman","year":"2005","journal-title":"J Rheumatol"},{"key":"2018112909313190000_40.5.647.24","first-page":"167","article-title":"Psoriasis: Severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity","volume":"16","author":"van de Kerkhof","year":"2006","journal-title":"Eur J Dermatol"},{"key":"2018112909313190000_40.5.647.25","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.391"},{"key":"2018112909313190000_40.5.647.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.23568"},{"key":"2018112909313190000_40.5.647.27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084244"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.120970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T13:22:48Z","timestamp":1543497768000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.120970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,15]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,5,1]]},"published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.3899\/jrheum.120970"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.120970","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,15]]}}}